Pao Group Stock Price, News & Analysis

PAO Group, Inc. (OTC PINK: PAOG) announced plans to expand its pharmaceutical development pipeline, focusing on additional products alongside the ongoing RespRx CBD project for Chronic Obstructive Pulmonary Disease (COPD). The company is reviewing opportunities with its CRO partner and other firms to enhance and diversify its offerings. Some identified projects have the potential for rapid revenue generation as early as 2022. More details are expected in the coming weeks.

PAO Group, Inc. (OTC Pink: PAOG) announced plans to release a third CBD nutraceutical product by year-end 2021, following the launch of its first two products, RelaxRX CBD and RehabRX CBD. The company confirmed a second production run for these products due to strong market response and has already shipped them to its distribution partner, North American Cannabis Holdings, Inc. PAOG aims to generate revenue in Q4 2021, leveraging its acquired extraction technology. Additionally, the company is developing a line of CBD women’s health products in collaboration with Alkame Holdings, Inc.

PAO Group, Inc. (OTC Pink: PAOG) announced the addition of bioidentical synthetic CBD to its research initiatives aimed at enhancing health benefits through its CBD pharmaceutical and nutraceutical developments. This move follows the ongoing evolution of hemp legalization, enabling the company to focus on more consistent and pure synthetic CBD, which has fewer contaminants. PAOG is also evaluating partnership opportunities to accelerate the development of its RespRx CBD pharmaceutical for Chronic Obstructive Pulmonary Disease (COPD) while identifying new fast-track pharmaceutical product development opportunities.

PAO Group, Inc. (OTC Pink: PAOG) is expanding its pharmaceutical pipeline by adding new products while continuing the development of its RespRx CBD treatment for Chronic Obstructive Pulmonary Disease (COPD). The company is currently reviewing this project with its Contract Research Organization (CRO) and industry experts to explore opportunities for acceleration and diversification.

Recent analyses have identified derivative opportunities that may lead to additional pharmaceutical developments, potentially reaching the market faster than RespRx.

PAO Group, Inc. (OTC Pink: PAOG) has announced plans to launch a CBD pet product line in December, capitalizing on the estimated $100 billion pet products market. The company, which holds intellectual property linked to its proprietary CBD extraction method (U.S. Patent No. 9,199,960), is also developing CBD nutraceuticals for humans. PAOG has confirmed shipping its initial products to North American Cannabis Holdings for online sales, anticipating revenue growth from these launches as it prepares additional follow-on products.

PAO Group, Inc. (OTC Pink: PAOG) announced it is seeking partnerships to enhance its RespRx CBD pharmaceutical for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment market is projected to grow from $9 billion in 2015 to $14.1 billion by 2025. PAOG recently acquired intellectual property related to CBD extraction (U.S. Patent No. 9,199,960) and is collaborating with Veristat to prepare an IND for FDA approval. The company has seen effectiveness in its trials for COPD and received inquiries regarding its RespRx developments, indicating strong market interest.

PAO Group, Inc. (OTC Pink: PAOG) announced its plans for a first acquisition by the end of 2021, aimed at expanding its product line and accelerating revenue growth. The company is initiating production of CBD nutraceuticals, with its first products, RelaxRX and RehabRX, expected to generate revenue in 2021. PAOG is leveraging its patented cannabis extraction method and plans to distribute through North American Cannabis Holdings, Inc. and partner with Puration, Inc. to enhance growth potential in the CBD market.

PAO Group, Inc. (OTC Pink: PAOG) announced the launch of its second CBD nutraceutical product, RehabRX CBD, aimed at enhancing skin health. This product, along with the earlier launched RelaxRX sleep aid, is part of PAOG's expanding CBD ‘RX’ brand line. Both products, which are gluten-free, non-GMO, and free from preservatives, will soon be available online and in retail locations through distribution partner North American Cannabis Holdings, Inc. PAOG anticipates rapid revenue growth as it develops a portfolio of pharmaceutical and nutraceutical treatments based on proprietary extraction technology.

PAO Group, Inc. (OTC Pink: PAOG) announced plans to develop CBD products for pets, with a product launch anticipated by year-end 2021. The company has secured intellectual property tied to a patented extraction method and recently launched its first CBD nutraceutical product, RelaxRX CBD, aimed at promoting sleep. PAOG expects to generate first revenue in Q4 2021 and anticipates rapid growth following the product launches. Products will be available through North American Cannabis Holdings, with plans for further offerings in the pipeline.